The Healthcare Specialist
Driven by Passion.
Powered by Science.
Passion is our driver and science is our foundation. At Rhenman & Partners we only invest in the healthcare sector and our investment process takes both scientific and financial aspects into consideration. The portfolio managers are supported in their investment decisions through close collaboration with our Scientific Advisory Board, which consists of experts within different medical fields.
Rhenman Healthcare Equity L/S is an AIF which is available to retail investors in Sweden and Finland only, and it is registered for professional investors only in Belgium, Finland, the Netherlands, Italy, Sweden, the United Kingdom, Singapore with restricted scheme offered to accredited investors only and Switzerland (distributed without FINMA registration.)
This is Rhenman & Partners
*As of XX-XX-XXXX (IC1 EUR)
Rhenman Healthcare Equity L/S (RHE L/S)
FUND CLASS | NAV | DEVELOPMENT 1 MONTH | THIS YEAR | SINCE FUND START | START DATE |
IC1 (EUR) | 815.93 | 1.94% | -10.98% | 715.93% | 2009-06-22 |
IC3 (EUR) | 1057.91 | 2.01% | -10.48% | 957.91% | 2009-07-31 |
IC2 (SEK) | 656.61 | 1.75% | -13.70% | 556.61% | 2012-12-31 |
ID1 (SEK) Distributing | 358.22 | 1.70% | -17.76% | 258.22% | 2012-04-30 |
IC1 (USD) | 216.52 | 2.33% | 0.97% | 116.52% | 2015-01-31 |
RC1 (EUR) | 691.57 | 1.89% | -11.34% | 591.57% | 2010-08-31 |
RC1 (SEK) | 750.02 | 1.65% | -14.37% | 650.02% | 2009-06-22 |
RC2 (SEK) | 805.13 | 1.70% | -14.05% | 705.13% | 2009-06-22 |
Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.
Rhenman Healthcare Equity L/S
Important information: Past performance is no guarantee of future returns. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back the entire invested capital.
FUND CLASS | NAV | DEVELOPMENT 1 MONTH | THIS YEAR | SINCE FUND START | START DATE |
IC1 (EUR) | 815.93 | 1.94% | -10.98% | 715.93% | 2009-06-22 |
IC3 (EUR) | 1057.91 | 2.01% | -10.48% | 957.91% | 2009-07-31 |
IC2 (SEK) | 656.61 | 1.75% | -13.70% | 556.61% | 2012-12-31 |
ID1 (SEK) Distributing | 358.22 | 1.70% | -17.76% | 258.22% | 2012-04-30 |
IC1 (USD) | 216.52 | 2.33% | 0.97% | 116.52% | 2015-01-31 |
RC1 (EUR) | 691.57 | 1.89% | -11.34% | 591.57% | 2010-08-31 |
RC1 (SEK) | 750.02 | 1.65% | -14.37% | 650.02% | 2009-06-22 |
RC2 (SEK) | 805.13 | 1.70% | -14.05% | 705.13% | 2009-06-22 |
Who we are
A team of healthcare specialists.
One of the key drivers of our success is our team of engaged portfolio managers, each specializing in a specific sub-sector - pharmaceuticals, biotech, medical technology, and healthcare services.
Their in-depth expertise is complemented by ongoing access to our Scientific Advisory Board, enabling them to identify emerging trends, breakthrough innovation and high-potential companies at an early stage.

The science behind
our portfolio managers.
Our dedicated Scientific Advisory Board consists of eminent medical experts, each with their own broad network of medical researchers and specialists around the world. This collaborative process provides invaluable insights for our investment decisions and enables us to take a higher, yet more balanced level of risk.
News
All
Direkt
Finwire
Uncategorized
Rhenman & Partners
Monthly comment (May 25): Another month overshadowed by worries over tariffs and trade barriers
Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop
Monthly comment – January 2025: All sectors except technology closing in positive territory
Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications
Subscribe to ‘News’
Read interesting news, the portfolio managers’ insights and the latest developments in the fund.